Keros Therapeutics KROS Cash Flow Statement (2019-2026)

NASDAQ KROS
$9.54 +0.21 (+2.25%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Keros Therapeutics Quarterly Cash Flow Statement

Periods 31 quarters
Latest Sep 2026

Keros Therapeutics reported cash from operations of $3.39M and free cash flow of $3.33M for the quarter ended Sep 2026, up 4.3% year over year. This cash flow statement covers 31 quarters of results from Mar 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-6.94M-24.19M-27.27M-23.51M-29.72M-35.80M-37.51M-39.44M-40.24M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-23.71M-28.71M14.15M
Depreciation and DepletionDep. & Depletion
0.10M0.11M0.31M0.13M0.13M0.17M0.19M0.21M0.25M0.28M0.31M0.31M0.33M0.34M0.37M0.40M0.40M0.40M0.40M0.38M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.10M0.11M0.31M0.13M0.13M0.17M0.19M0.21M0.25M0.28M0.31M0.31M0.33M0.34M0.37M0.40M0.40M0.40M0.40M0.38M
Share-based CompensationStock Comp.
3.30M4.39M4.79M4.75M4.75M5.69M7.04M8.71M7.32M8.07M8.79M8.82M9.20M8.86M8.54M3.99M7.31M6.20M5.38M4.20M
Gains from Sales and DivestituresGains Divest
-0.03M-0.01M0.00M0.00M0.00M
Other non-cash itemsOther Non-Cash
0.20M0.20M3.38M3.71M0.32M0.52M0.34M0.34M0.35M0.56M0.57M0.58M0.60M0.61M0.62M0.64M0.65M0.67M
Change in Working Capital
Change in ReceivablesChange Receivables
18.00M-18.00M0.14M0.08M-0.22M0.38M2.35M14.55M-1.48M-12.32M0.08M-3.17M-0.40M20.00M
Change in Account PayablesChange Payables
0.82M-0.67M4.66M-4.99M0.60M1.32M-0.57M-0.18M1.04M0.02M1.61M-1.59M-0.29M2.02M-1.37M-2.96M-0.70M-0.11M0.32M1.97M
Change in Accrued ExpensesChange Accrued Exp.
-0.10M0.36M-0.58M1.28M4.26M-1.98M1.17M0.27M5.79M-5.35M0.90M8.71M-1.30M-3.58M2.67M-4.80M-4.43M-5.22M2.22M0.92M
Change in TaxesChange Taxes
10.04M-3.72M-2.17M-6.40M0.62M
Change in Other Operating AssetsOther Assets Change
-2.04M-0.76M4.10M1.29M0.27M4.07M1.49M4.26M-0.06M4.48M6.39M-6.36M5.72M-6.14M4.64M-4.43M-0.14M-15.67M0.50M-1.10M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.02M-0.40M-0.61M1.01M-0.08M-0.03M0.36M-0.26M-1.32M3.31M-2.38M-0.77M-2.13M
Other Working Capital ChangesOther WC Changes
2.02M0.36M-4.71M-0.28M-0.27M-4.16M-1.52M-3.90M-0.19M-4.48M-6.39M6.36M-7.04M9.44M-7.02M3.66M-1.99M15.67M-0.50M1.10M
Cash from OperationsCash from Ops.
-19.57M-1.43M-22.59M-24.60M-21.44M-34.24M-30.83M-33.98M-25.46M-44.56M-39.80M-30.50M-46.01M161.17M-29.62M3.25M-27.29M-3.53M-20.42M3.39M
Investing Activities
Capital ExpendituresCapex
0.16M0.15M0.57M0.18M0.35M1.06M0.31M0.55M0.54M0.95M0.31M0.39M0.29M0.57M0.72M0.13M0.13M0.07M0.16M0.06M
Change in Property, Plant and EquipmentChange in PP&E
-0.16M-0.15M-0.57M-0.18M-0.35M-1.06M-0.31M-0.55M-0.54M-0.95M-0.31M-0.39M-0.29M-0.57M-0.72M-0.13M-0.13M-0.07M-0.16M-0.06M
Other Investing Activities (as filed)Other investing (as filed)
0.00M1.33M1.33M1.33M1.33M1.33M1.21M1.21M0.24M1.45M1.45M1.45M
Cash from Investing ActivitiesCash from Investing
-0.16M-0.15M-0.57M-0.18M-0.35M-1.06M-0.31M-0.55M-0.54M-0.95M-0.31M-0.39M-0.29M-0.57M-0.72M-0.13M-0.13M-0.07M-0.16M-0.06M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M0.13M0.01M0.02M0.08M
Shares Repurchased
375.00M
Net Shares Issued and RepurchasedNet Shares Issued
0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M-374.87M0.01M0.02M0.08M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M-374.87M0.01M0.02M0.08M
Other financing activities (as filed)
-0.09M-0.09M-0.26M-0.02M-0.17M0.14M
Cash from Financing ActivitiesCash from Financing
28.42M0.12M10.19M48.58M61.42M107.68M1.74M0.28M69.25M156.80M3.53M155.94M75.54M0.00M0.02M0.14M-378.63M-2.32M-3.32M-1.47M
Additional items
Change in Cash
8.69M-1.46M-12.97M23.81M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M-5.92M-23.89M1.86M
Ending Cash Balance
231.37M229.91M216.95M240.75M280.38M352.76M323.35M289.11M332.36M443.66M407.08M532.13M561.38M721.99M691.66M694.92M288.86M282.95M259.06M260.91M
Free Cash FlowFCF
-19.72M-1.57M-23.16M-24.78M-21.79M-35.30M-31.14M-34.53M-26.00M-45.51M-40.11M-30.89M-46.30M160.61M-30.34M3.12M-27.43M-3.60M-20.58M3.33M
Net Cash FlowNCF
8.69M-1.46M-12.97M23.81M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M-5.92M-23.89M1.86M
Income Taxes PaidTaxes Paid
0.75M4.95M

Keros Therapeutics Cash Flow Statement API

Pull Keros Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=KROS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY